J Neurol Sci 2003 Feb 15;206(2):215-6
Leary SM, Thompson AJ.
NMR Research Unit, Institute of Neurology, University College London, Queen Square, WC1N 3BG, London, UK
There is currently no disease-modifying treatment proven to be of efficacy in primary progressive multiple sclerosis (PPMS).
However, a number of therapeutic trials have recently been specifically designed for this group.
These include a randomised controlled trial of interferon beta-1a which is discussed here.
It is hoped that therapeutics in primary progressive
multiple sclerosis will continue to expand and effective therapeutic agents
will be developed.